pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), ... versus platinum-based chemotherapy, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 1.01 [0.78, 1.32]< 10%2 studies (2/-)46.8 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 0.36 [0.22, 0.60]< 179%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
DCR 3.84 [2.04, 7.23]> 10%1 study (1/-)100.0 %NAnot evaluable non important-
objective responses (ORR) 5.38 [3.64, 7.98]> 120%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

TRAE (any grade) 0.70 [0.07, 6.83]< 10%1 study (1/-)61.9 %NAnot evaluable non important-
TRAE (grade 3-4) 0.61 [0.24, 1.54]< 188%2 studies (2/-)85.2 %some concernnot evaluable moderatenon important-
TRAE leading to death (grade 5) 1.28 [0.16, 10.22]< 15%2 studies (2/-)40.8 %some concernnot evaluable moderatenon important-
TRAE leading to discontinuation (any grade) 0.26 [0.03, 1.97]< 194%2 studies (2/-)90.2 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.